Skip to main content
Fig. 5 | Molecular Medicine

Fig. 5

From: Insulin-like Growth Factor I and Urokinase-type Plasminogen Activator Bioregulation System as a Survival Mechanism of Prostate Cancer Cells in Osteoblastic Metastases: Development of Anti-Survival Factor Therapy for Hormone-Refractory Prostate Cancer

Fig. 5

Patient with stage D2 prostate cancer response to complete androgen blockade.

The clinical response (as presented by the follow-up of PSA values) in a patient with stage D2 prostate cancer who was treated with complete androgen blockade [(CAB) GnRH-A; triptorelin 3,75 mg i.m. q28D plus flutamide; 250 mg tid p.o.] for 7 months before he progressed to stage D3, hormone refractory, prostate cancer. CAB plus salvage chemotherapy (M + P), employing mitoxantrone (10 mg/M2, i.v. q3 weeks) and prednisolone (10 mg, i.m., qD for the first week in each cycle) produced no response. Moreover, flutamide withdrawal (AW) did not affect disease progression. Patient was put on combination therapy using anti-survival factor therapy [(ASF) dexamethasone 4 mg p.o. qD, tapered to 2 mg qD within 3 months] and somatostatin analog (lanreotide 30 mg, i.m., q14D)] and GnRH-A (triptorelin, 3,75 mg i.m. q28D). This patient experienced an impressive clinical response (decrease of PSA to normal values and excellent performance status). (18,19) PSA = prostate-specific antigen.

Back to article page